Sun Pharmaceuticals

In the near term, pricing pressure in generics and moderation in contribution from Revlimid is a key watch, along with potential tariff announcements by the US

Buy Sun Pharmaceuticals; target of Rs 2264: Sharekhan

Sharekhan is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2264 in its research report dated October 28, 2024.

Buy Sun Pharmaceuticals; target of Rs 1800: Sharekhan

Sharekhan is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1800 in its research report dated June 20, 2024.

Buy Sun Pharmaceuticals; target of Rs 1827: KR Choksey

KR Choksey is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1827 in its research report dated March 19, 2024.

Sun Pharma, Lupin, Alkem recall products from US market

Sun Pharma is recalling 54,960 bottles of Mesalamine Extended-Release Capsules, an anti-inflammatory medicine used to treat a type of bowel disease known as ulcerative colitis

Sun Pharma hits 52-week high on acquiring Israeli company

Libra Merger Ltd is Sun’s second buy in Israel after Taro Pharma, a high-profile acquisition for the Indian drug company

Top Nifty gainers and losers at mid-day: Hindalco up, Power Grid down

About 2098 shares advanced, 1082 shares declined, and 103 shares unchanged.

Improved sentiment, hopes of better sales fuel gains in pharma stocks; Divi's Lab spurts 8%

Multiple counters in the pharmaceutical space, including Divi's Laboratories, Cipla, Sun Pharmaceuticals, Lupin, and Natco Pharma also witnessed large deals on April 12.

Taken prompt steps to contain impact of IT security incident, ransomware group claims responsibility: Sun Pharma

On March 2, an information security incident occurred at the premises of Sun Pharma after which the company isolated the impacted IT assets.

Sun Pharma to get growth boost with addition of Deuroxolitinib to its speciality portfolio: Analysts

Brokers remain positive about the acquisition and believe in the growth potential of Deuroxolitinib, which is a part of Concert's patent portfolio

Quant Pick - Sun Pharmaceuticals: ICICI Direct

According to ICICI Direct, Buy Sun Pharmaceuticals in range of Rs 625-635 Target: Rs 738 Stop Loss: Rs 570 Time frame: Three months.

Buy Sun Pharmaceuticals; target of Rs 660: Dolat Capital

Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 660 in its research report dated September 21, 2020.

Buy Sun Pharmaceuticals; target of Rs 571: Dolat Capital

Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 571 in its research report dated August 01, 2020.

Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital

Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 530 in its research report dated June 11, 2020.

Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital

Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 530 in its research report dated May 27, 2020.

Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct

ICICI Direct recommended hold rating on Sun Pharmaceuticals with a target price of Rs 460 in its research report dated February 13, 2019.

Hold Sun Pharmaceuticals; target of Rs 460: ICICI Direct

ICICI Direct recommended hold rating on Sun Pharmaceuticals with a target price of Rs 460 in its research report dated December 04, 2018.

Buy Sun Pharmaceuticals; target of Rs 690: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 690 in its research report dated August 16, 2018.

Sun Pharma recalls over 5.2k units of testosterone cypionate injections from US

The injections are used for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone.

Sun Pharmaceuticals Q1 PAT seen up 68.7% YoY to Rs. 886.9 cr: Kotak

Net Sales are expected to increase by 14.3 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 7,096.3 crore, according to Kotak.

Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss

Edelweiss recommended hold rating on Sun Pharmaceuticals with a target price of Rs 480 in its research report dated May 25, 2018.

Hold Sun Pharmaceuticals; target of Rs 510: ICICI Direct

ICICI Direct is recommended hold rating on Sun Pharmaceuticals with a target price of Rs 510 in its research report dated May 28, 2018.

Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss

Edelweiss recommended hold rating on Sun Pharmaceuticals with a target price of Rs 480 in its research report dated April 05, 2018.

Sun Pharmaceuticals Q2 PAT may dip 62.3% YoY to Rs. 848.7 cr: Kotak

Net Sales are expected to decrease by 15.2 percent Y-o-Y (up 12.8 percent Q-o-Q) to Rs. 7006.1 crore, according to Kotak.

Analysts consensus is bearish on pharma stocks – should one buy?

All generic pharmaceutical companies across the world and those involved in the distribution of generic drugs in the USA have seen their market value eroding sharply.